MS-N167 · Standardized botanical product · Fatigue support · Colorectal cancer on mFOLFOX6 · Double-blind phase III trial · Appraised 28 October 2026

Does Korean red ginseng reduce cancer-related fatigue during mFOLFOX6 chemotherapy for colorectal cancer?

Evidence at a glance

• Evidence label: Positive product-specific phase III signal with safety and sponsorship caveats
• Benefit: The prespecified fatigue AUC analysis favored Korean red ginseng, with improvement in selected Brief Fatigue Inventory domains.
• Certainty: Moderate. The trial randomized 438 people and was double blind, but published reporting emphasizes selected domains and per-protocol findings; absolute clinical importance requires cautious interpretation.
• Risk: Neutropenia was more frequent with ginseng, although overall adverse-event incidence was similar. Insomnia, blood-glucose effects and medicine interactions remain relevant.

What was studied

Four hundred thirty-eight people receiving mFOLFOX6 for colorectal cancer were randomized to Korean red ginseng 2,000 mg/day (219) or matching placebo (219) for 16 weeks. The primary endpoint was mean area-under-the-curve change from baseline in the Brief Fatigue Inventory; fatigue-related quality of life, stress and adverse events were secondary. The trial was registered as NCT02039635.

What the evidence found

The full-analysis AUC comparison favored ginseng, with significant differences reported for the mood and walking-ability interference domains (P=0.038 and P=0.023). In the per-protocol population, global BFI favored ginseng (P=0.019). Overall adverse events were similar, but neutropenia occurred more often with ginseng.

How to interpret it

This is stronger evidence than most botanical-fatigue studies, but it is product- and regimen-specific and does not prove that other ginseng products work. Fatigue improvement does not imply better tumor response or survival. Sponsorship by Korea Ginseng Corporation increases the importance of independent replication.

Practical safety context

Review ginseng with the oncology pharmacist, especially with anticoagulants, diabetes medicines, blood-pressure medicines, antidepressants or insomnia. Fever during neutropenia is an emergency. Do not use fatigue relief to mask infection, anemia, dehydration or disease progression.

Questions for the care team

• Is the proposed product chemically comparable to the studied Korean red ginseng?
• How will neutrophil counts and fatigue be monitored?
• Could insomnia, blood sugar or medicine interactions outweigh a modest benefit?

Funding and conflicts

Supported by Korea Ginseng Corporation. The authors reported no conflicts of interest; commercial sponsorship remains an important appraisal consideration.

Sources

• Phase III trial (PMID 32172198)
• DOI 10.1016/j.ejca.2020.02.018
• ClinicalTrials.gov NCT02039635
• NCCIH Asian ginseng safety summary

Last literature search: 28 October 2026. Record appraisal: 28 October 2026. This page is educational and does not replace individualized medical advice. Symptom, biomarker or observational findings must not be interpreted as proof of tumor control, recurrence prevention or longer survival unless those outcomes were directly tested.